Core Viewpoint - The article discusses the recent approval of clinical trials for Semaglutide injection by Taiji Group's subsidiary, indicating a significant step in the GLP-1 drug market in China, which is currently dominated by Novo Nordisk's product. Group 1: Clinical Trial Approval - Taiji Group's subsidiary, Fuling Pharmaceutical Factory, has received the clinical trial approval notice from the National Medical Products Administration for Semaglutide injection [2] - The clinical trial is aimed at adult patients with type 2 diabetes who have not achieved blood sugar control despite using metformin and/or sulfonylureas, as well as those with cardiovascular diseases [6] Group 2: Market Competition - As of the announcement date, Novo Nordisk is the only company with an approved Semaglutide injection in China, generating significant revenue of $29.296 billion in 2024 [7] - Taiji Group's entry into the GLP-1 market signifies the emergence of new competition, with the company claiming advantages in quality and large-scale production through efficient yeast expression technology [7] Group 3: Research and Development Investment - The cumulative R&D investment for the Semaglutide project by Taiji Group is approximately RMB 44.1834 million (unaudited) [8] - Following the approval, Fuling Pharmaceutical Factory will initiate clinical trials and submit data to the regulatory authority for production and market approval [8] Group 4: Company Overview - Taiji Group is a large pharmaceutical manufacturing enterprise in China, involved in traditional Chinese medicine, chemical drugs, and active pharmaceutical ingredients [9] - The company's move into the GLP-1 target is viewed as a crucial step towards its transformation into modern biopharmaceuticals [9]